Algert Global LLC Ascendis Pharma A/S Transaction History

Algert Global LLC

$2.55 Billion
Q1 2024

A detailed history of Algert Global LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Algert Global LLC holds 1,410 shares of ASND stock, worth $189,193. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,410

Holding current value

$189,193

% of portfolio

0.01%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$123.45 - $159.4 $174,064 - $224,754	1,410 New	1,410 $213,000
Q1 2023 May 12, 2023	BUY	$104.9 - $126.78 $291,517 - $352,321	2,779 New	2,779 $298,000
Q1 2021 May 14, 2021	SELL	$124.92 - $173.33 $944,395 - $1.31 Million	-7,560 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$151.2 - $182.76 $246,153 - $297,533	-1,628 Reduced 17.72%	7,560 $1.26 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $187,200 - $215,122	1,394 Added 17.89%	9,188 $1.42 Million

Q2 2020 Aug 12, 2020	SELL	$110.87 - $156.01 $300,679 - $423,099	-2,712 Reduced 25.81%	7,794 $1.15 Million
Q1 2020 May 13, 2020	BUY	$97.01 - $145.11 $1.02 Million - $1.52 Million	10,506 New	10,506 $1.18 Million

Others Institutions Holding ASND

# of Institutions

211

Shares Held

46.5M

Call Options Held

310K

Put Options Held

306K

Artisan Partners Limited Partnership Milwaukee, WI

5.67M
Shares

$761 Million
1.32% of portfolio
Westfield Capital Management CO LP Boston, MA

4.08M
Shares

$547 Million
3.29% of portfolio
Avoro Capital Advisors LLC New York, NY

3.97M
Shares

$532 Million
7.23% of portfolio
Janus Henderson Group PLC London, X0

3.77M
Shares

$505 Million
0.32% of portfolio
Wellington Management Group LLP Boston, MA

2.75M
Shares

$368 Million
0.08% of portfolio

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.49B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account